wedzicha
ja
respiratori
syncyti
viru
airway
inflamm
declin
patient
chronic
obstruct
pulmonari
diseas
j
respir
crit
care
med
paper
demonstr
persist
respiratori
syncyti
viru
infect
could
contribut
progress
copd
sever
model
infect
exacerb
copd
papi
et
al
wwwsciencedirectcom
alberto
papi
marco
contoli
caramori
gaetano
patrick
mallia
sebastian
l
johnston
despit
optim
use
current
avail
therapi
stabl
copd
acut
exacerb
common
event
constitut
major
health
burden
develop
highli
sensit
diagnost
tool
highlight
role
viral
infect
induc
copd
exacerb
rhinovirus
frequent
identifi
viru
type
far
littl
known
mechan
virusinduc
exacerb
recent
develop
first
human
rhinovirusinduc
copd
exacerb
model
repres
invalu
tool
toward
increas
knowledg
immunolog
inflammatori
mechan
copd
exacerb
model
give
us
opportun
highlight
key
inflammatori
mediat
repres
possibl
therapeut
target
develop
novel
drug
abl
treat
prevent
acut
episod
copd
chronic
obstruct
pulmonari
diseas
copd
characteris
fix
airway
obstruct
associ
abnorm
inflamm
airway
occur
suscept
subject
expos
noxiou
particl
gase
frequent
cigarett
smoke
clinic
histori
copd
punctuat
recurr
acut
exacerb
episod
acut
onset
worsen
patient
clinic
statu
characteris
dyspnea
wheez
cough
sputum
product
besid
acut
clinic
present
assess
sever
exacerb
also
base
patient
medic
histori
exacerb
includ
sever
airway
obstruct
preexist
comorbid
durat
magnitud
symptom
physic
examin
arteri
blood
ga
measur
acut
exacerb
common
occurr
copd
patient
frequenc
exacerb
increas
sever
diseas
addit
major
caus
copdassoci
morbid
mortal
exacerb
contribut
impair
health
statu
loss
lung
function
thu
diseas
progress
estim
acut
exacerb
also
caus
healthcar
cost
associ
copd
thank
develop
highli
sensit
diagnost
tool
evid
bacteri
also
viral
infect
major
caus
copd
exacerb
tabl
although
sever
mechan
propos
explain
bacteri
infect
trigger
copd
exacerb
includ
induct
mucu
hypersecret
reduct
ciliari
beat
frequenc
enhanc
neutrophil
inflamm
data
avail
pathogenesi
virusinduc
exacerb
bronchodil
corticosteroid
indic
antibiot
repres
current
recommend
pharmacolog
treatment
copd
exacerb
date
treatment
evaluateddesign
specif
prevent
treat
virusinduc
copd
exacerb
thu
develop
model
virusinduc
copd
exacerb
fundament
step
toward
increas
knowledg
relev
pathogenet
mechan
well
provid
invalu
tool
identifi
test
novel
pharmacolog
target
current
review
briefli
review
data
current
avail
role
respiratori
virus
copd
exacerb
focu
particularli
vitro
vivo
model
virusinduc
copd
exacerb
copd
exacerb
associ
increas
number
activ
inflammatori
cell
airway
chronic
inflamm
copd
character
increas
number
lymphocyt
infiltr
central
peripher
airway
increas
upon
exacerb
among
possibl
caus
recruit
airway
chronic
viral
infect
suggest
particularli
import
attent
given
possibl
role
latent
adenovir
infect
pathogenesi
copd
recent
document
copd
patient
repeat
presenc
respiratori
syncyti
viru
sputum
two
year
faster
lung
function
declin
time
taken
togeth
data
indic
respons
repeatedlat
viral
infect
excess
recruit
lymphocyt
might
occur
tracheobronchi
tree
driven
inflamm
damag
lung
suscept
smoker
lead
copd
progress
use
highli
sensit
diagnost
method
pcr
viral
detect
biolog
sampl
shown
proport
virusinduc
copd
exacerb
like
outpati
set
hospitalis
patient
rhinovirus
frequent
identifi
viru
type
recent
studi
address
rel
import
viral
versu
bacteri
infect
aetiolog
sever
hospitalis
copd
exacerb
viral
andor
bacteri
infect
detect
approxim
copd
exacerb
bacteri
viral
viralbacteri
coinfect
infecti
exacerb
led
longer
hospitalis
greater
impair
sever
measur
lung
function
noninfecti
exacerb
importantli
exacerb
coinfect
result
mark
lung
function
impair
longer
hospitalis
similarli
outpati
set
copd
exacerb
greater
declin
lung
function
document
patient
bacteri
infect
cold
symptom
present
simultan
understand
mechan
virusassoci
asthma
exacerb
rel
poor
even
less
known
pathogenesi
virusassoci
copd
exacerb
copd
exacerb
sever
inflammatori
mediat
increas
airway
howev
littl
known
inflammatori
mediat
specif
virusinduc
copd
exacerb
one
studi
found
increas
sputum
interleukin
il
virusassoci
acut
episod
compar
nonvir
exacerb
recent
presenc
rhinoviru
haemophilu
influenza
exacerb
associ
increas
level
serum
suggest
virus
bacteria
synergist
interact
increas
sever
inflamm
occur
exacerb
major
group
rhinovirus
account
total
rhinoviru
type
attach
airway
epithelium
intercellular
adhes
molecul
interestingli
rhinoviru
infect
induc
express
receptor
might
promot
inflammatori
cell
recruit
activ
inde
evid
upregul
bronchial
mucosa
patient
chronic
bronchiti
thu
one
possibl
mechan
increas
airway
inflamm
rhinovirusinduc
lower
airway
inflamm
could
occur
via
upregul
natur
inflammatori
cell
recruit
lung
copd
exacerb
fulli
clarifi
studi
analys
bronchial
biopsi
exacerb
difficulti
associ
perform
invas
procedur
acut
ill
patient
two
studi
use
bronchial
biopsi
exacerb
chronic
bronchiti
singl
cohort
patient
report
promin
airway
eosinophilia
togeth
increas
number
neutrophil
lymphocyt
exacerb
group
compar
stabl
patient
anoth
recent
studi
show
increas
number
neutrophil
sputum
exacerb
increas
independ
pathogen
detect
studi
document
virusinduc
copd
exacerb
without
concomit
bacteri
infect
associ
increas
number
eosinophil
sputum
suggest
sputum
eosinophilia
could
marker
viral
infect
copd
exacerb
interestingli
increas
number
sputum
lymphocyt
report
copd
exacerb
rel
reduct
ratio
interferon
ifn
lymphocyt
thu
switch
toward
phenotyp
immun
respons
exacerb
could
one
potenti
mechan
involv
recruit
eosinophil
respiratori
tabl
pathogen
identifi
copd
exacerb
method
use
detect
whether
copd
patient
suscept
viru
infect
compar
normal
subject
strongli
debat
recent
studi
document
patient
frequent
copd
exacerb
frequent
episod
natur
occur
cold
compar
patient
infrequ
exacerb
result
suggest
copd
subject
frequent
exacerb
repres
subgroup
particularli
suscept
viral
infect
thu
although
solid
evid
impair
innat
possibl
acquir
immun
respons
viral
infect
asthmat
patient
yet
clear
whether
copd
patient
increas
suscept
viral
infect
intriguingli
patient
experienc
frequent
cold
significantli
higher
exposur
cigarett
smoke
use
mous
model
cigarett
smoke
exposur
recent
demonstr
cigarett
smoke
increas
suscept
viral
infect
possibl
via
alter
andor
inhibit
immun
respons
therefor
could
specul
cigarett
smoke
exposur
import
risk
factor
develop
copd
might
caus
impair
immun
respons
viral
infect
copd
patient
anoth
mechan
might
lead
increas
suscept
viral
infect
upregul
receptor
major
group
human
rhinovirus
latent
express
adenovir
protein
alveolar
epitheli
cell
patient
emphysema
increas
express
could
explain
greater
suscept
rhinoviru
infect
copd
solid
evid
show
patient
copd
chronic
colon
airway
bacteria
bacteri
load
relat
airway
inflamm
diseas
progress
postul
bacteri
colonis
contribut
increas
suscept
viral
infect
copd
patient
exampl
increas
express
bronchial
epitheli
cell
either
directli
induc
inflamm
studi
requir
investig
interact
chronic
bacteri
colonis
respiratori
viral
infect
particular
whether
chronic
bacteri
colonis
increas
suscept
viral
infect
vice
versa
vitro
respiratori
viru
infect
bronchial
epitheli
cell
macrophag
induc
product
sever
proinflammatori
molecul
relev
pathogenesi
copd
exacerb
howev
although
vitro
model
provid
import
insight
molecular
mechan
inflammatori
antivir
respons
viral
bacteri
infect
insight
requir
valid
vivo
model
present
publish
anim
model
copd
exacerb
either
virusassoci
bacteriainduc
copd
exacerb
thu
reli
exclus
human
studi
littl
data
avail
date
perform
studi
natur
occur
copd
exacerb
prove
difficult
sever
reason
includ
nonreport
exacerb
patient
lack
baselin
data
exacerb
wide
variat
etiolog
variat
time
sampl
rel
onset
exacerb
final
difficulti
carri
invas
airway
investig
acut
unwel
patient
one
way
overcom
obstacl
develop
human
experiment
model
would
allow
studi
take
place
control
condit
first
step
toward
develop
model
realis
recent
report
first
studi
evalu
effect
experiment
viral
infect
copd
patient
pilot
studi
mild
copd
patient
select
experiment
infect
purpos
firstli
evalu
whether
procedur
safe
copd
patient
secondli
provid
preliminari
data
whether
experiment
rhinoviru
infect
copd
patient
suffici
trigger
exacerb
per
se
safeti
prime
concern
care
design
rhinoviru
doseescal
studi
perform
small
group
subject
determin
minimum
dose
viru
abl
induc
clinic
cold
inocul
subject
ie
surprisingli
first
four
patient
expos
initi
lowest
dose
rhinoviru
inoculum
experienc
cold
symptom
also
lower
respiratori
tract
symptom
includ
short
breath
wheez
cough
increas
sputum
product
eg
symptom
copd
exacerb
moreov
experiment
rhinoviru
infect
induc
signific
fall
lung
function
typic
natur
occur
exacerb
sever
exacerb
induc
mildtomoder
thu
achiev
primari
aim
studi
show
experiment
rhinoviru
infect
could
safe
carri
mild
copd
patient
model
also
show
experiment
rhinoviru
infect
caus
exacerb
copd
patient
perform
use
larger
number
patient
includ
assess
lower
airway
inflammatori
respons
potenti
provid
valid
model
natur
occur
copd
exacerb
copd
yet
scenario
specif
aetiolog
experiment
proven
induc
exacerb
model
offer
possibl
investig
specif
immunolog
inflammatori
event
drive
transit
stabl
state
exacerb
rhinoviru
infect
two
potenti
import
preliminari
observ
aros
studi
copd
patient
develop
cold
exacerb
lower
dose
viru
use
previou
studi
asthmat
normal
volunt
day
gap
peak
cold
symptom
peak
lower
respiratori
symptom
figur
data
suggest
copd
patient
may
highli
suscept
viru
infect
effect
antivir
antiinflammatori
treatment
given
onset
cold
symptom
might
possibl
chang
clinic
outcom
infect
copd
preliminari
find
clearli
requir
confirm
larger
number
patient
similar
experiment
model
asthmat
patient
recent
document
sever
virusinduc
exacerb
term
symptom
lung
function
reduct
inflamm
airway
invers
relat
product
novel
class
interferon
call
ifnl
impair
innat
immun
respons
might
therefor
one
mechan
asthmat
patient
shown
increas
suscept
respiratori
viral
infect
new
human
model
virusinduc
copd
exacerb
give
us
opportun
test
whether
similar
differ
immun
defici
present
copd
whether
modul
andor
restor
immun
respons
could
repres
effect
novel
pharmacolog
approach
treat
prevent
copd
exacerb
develop
experiment
model
causat
clearli
defin
detail
clinic
studi
mechan
diseas
carri
major
step
forward
abil
perform
studi
aim
increas
understand
clinic
relev
condit
bronchodil
gold
standard
copd
treatment
diseas
sever
intern
guidelin
recommend
combin
therapi
bronchodil
inhal
steroid
therapeut
regimen
provid
benefici
effect
symptom
control
copd
patient
also
evid
reduc
frequenc
exacerb
nevertheless
despit
optim
therapi
exacerb
still
occur
aim
copd
exacerb
manag
reliev
symptom
airway
obstruct
correct
hypoxia
hypercapnia
present
treat
precipit
factor
andor
comorbid
involv
number
modal
treatment
includ
pharmacolog
therapi
oxygen
therapi
indic
mechan
ventil
inhal
bronchodil
system
corticosteroid
shown
benefici
acut
exacerb
copd
convers
role
effect
antibiot
acut
exacerb
copd
still
debat
recent
metaanalysi
support
use
antibiot
copd
exacerb
patient
moderatetosever
ill
increas
cough
sputum
purul
analysi
restrict
communitybas
studi
find
differ
antibiot
placebo
howev
survey
antibiot
prescrib
copd
exacerb
clinic
practic
indic
use
major
exacerb
commun
hospit
practic
thu
larg
number
patient
probabl
receiv
inappropri
antibiot
figur
upper
urt
lower
respiratori
tract
lrt
symptom
copd
patient
vivo
experiment
infect
rhinoviru
gap
peak
cold
symptom
peak
lower
respiratori
symptom
document
modifi
data
suggest
effect
antivir
antiinflammatori
treatment
could
given
onset
cold
symptom
could
possibl
chang
clinic
outcom
viral
infect
copd
therapi
associ
increas
cost
risk
antibiot
resist
therefor
urgent
need
develop
simpl
clinic
biolog
marker
identifi
patient
highest
risk
bacteri
infect
well
benefit
antibiot
therapi
none
clinic
trial
conduc
far
investig
whether
current
avail
therapi
copd
specif
prevent
andor
treat
virusinduc
exacerb
thu
studi
need
elucid
mechan
lead
viral
infect
trigger
copd
exacerb
thu
identifi
key
inflammatori
mediat
andor
immunolog
pathway
develop
novel
drug
abl
treat
prevent
acut
episod
copd
inde
far
antivir
therapi
focus
mainli
vaccin
optim
prevent
strategi
subsequ
develop
antivir
agent
lag
behind
antibacteri
chemotherapi
vaccin
might
realist
option
treatment
respiratori
viral
infect
view
varieti
differ
virus
caus
similar
clinic
syndrom
develop
vaccin
rhinovirus
especi
problemat
larg
number
differ
serotyp
recognit
rhinovirus
associ
sever
clinic
syndrom
upper
respiratori
tract
infect
stimul
research
antirhinovir
agent
number
antirhinovir
drug
develop
date
agent
approv
treatment
rhinoviru
infect
specif
strategi
abl
interfer
pathogenesi
virusinduc
exacerb
real
futur
challeng
expect
copd
third
greatest
caus
death
worldwid
major
morbid
mortal
healthcar
cost
copd
caus
exacerb
thank
use
novel
highli
sensit
diagnost
tool
role
respiratori
virus
copd
exacerb
emerg
past
year
nevertheless
mechan
lead
copd
exacerb
respiratori
viru
infect
still
larg
unknown
recent
develop
first
human
model
virusinduc
copd
exacerb
demonstr
feasibl
far
safe
facilit
identif
novel
pharmacolog
target
provid
opportun
develop
new
treatment
exacerb
copd
